03:50 PM EDT, 09/25/2025 (MT Newswires) -- Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each falling about 1.6%.

The iShares Biotechnology ETF (IBB) fell 1.8%.

In corporate news, Acadia Pharmaceuticals' ( ACAD ) topline data from its phase 3 trial of ACP-101 in Prader-Willi syndrome was a "clear failure across the board," Deutsche Bank said in a note. Deutsche Bank cut its price target to $29 from $35 while keeping its buy rating. Acadia shares were down 0.6%.

Philips (PHG) is in talks with US policymakers regarding investigations into imports of medical equipment, but doesn't expect any immediate impact from the probes, Reuters reported. Philips shares were falling 3.1%.

Capricor Therapeutics ( CAPR ) shares rose 6% after it gave a regulatory update on its biologics license application for deramiocel in Duchenne muscular dystrophy therapy following a Type A meeting with the US Food and Drug Administration.